Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07637942 · ClinicalTrials.gov registry record
Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
A clinical trial, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- Not yet
- Registry status
- 40
- Enrollment target
NCT07637942 is a clinical trial that has not yet begun recruiting, run by International Maternal Pediatric Adolescent AIDS Clinical Trials Group. The registered enrollment target is 40 participants.
The verdict
NCT07637942 has not yet begun recruiting, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- NOT YET RECRUITING
- Registry status
- 40 participants
- Enrollment target
Study Summary
Phase IV, multi-site, open-label, non-randomized study of the pharmacokinetics (PK) of long-acting injectable cabotegravir and rilpivirine (CAB LA + RPV LA) during pregnancy and postpartum.
Interventions
- DRUG Every 4-week long-acting injectable cabotegravir and rilpivirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2028-02-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07637942
The ClinicalTrials.gov registry entry for NCT07637942 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International Maternal Pediatric Adolescent AIDS Clinical Trials Group, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Every 4-week long-acting injectable cabotegravir and rilpivirine is the first listed.
NCT07637942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07637942 about?
NCT07637942 is a clinical study titled "Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy". Phase IV, multi-site, open-label, non-randomized study of the pharmacokinetics (PK) of long-acting injectable cabotegravir and rilpivirine (CAB LA + RPV LA) during pregnancy and postpartum.
What is the current status of trial NCT07637942?
This trial is currently not yet recruiting. The enrollment target is 40 participants. The study started on 2026-07-15. Estimated completion is 2028-02-15.
What interventions are being tested in trial NCT07637942?
The interventions under investigation include: Every 4-week long-acting injectable cabotegravir and rilpivirine (DRUG).
Who is sponsoring clinical trial NCT07637942?
This trial is sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.